Erasca, Inc.
Erasca, Inc. (ERAS) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · ERAS · as of Jun 8, 2026
Key Statistics
Explore Erasca, Inc. Data
eras stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 11 · Buy rate: 81.8%
The ERAS analyst consensus is Buy, based on ratings from 11 Wall Street analysts over the past 3 months. The average 12-month price target is $17.50, representing +38.45% upside from the current price of $12.64.
Competitors & Peers
eras competitorsERAS
ARVN
ATXS
AVBP
CRVS
CTMXStock Performance
Full HistoryAbout Erasca, Inc.
Erasca, Inc. a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candid…
what is erasca, inc. · eras stock overview · erasca, inc. company profile · who is erasca, inc. ceo · eras NASDAQ · erasca, inc. headquarters · erasca, inc. business segments
About Stock Overview & Key Data
Erasca, Inc. (ERAS) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jul 16, 2021. As of the latest trading session, ERAS stock price is $12.64, with a market capitalization of $3.9B. The stock has returned +634.36% over the past 12 months and +221.77% year-to-date.
According to 11 Wall Street analysts, the consensus rating for Erasca, Inc. stock is Buy, with an average 12-month price target of $17.50. In fiscal year 2025, Erasca, Inc. reported revenue of — and net income of -$124.5M. For detailed data — including Erasca, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Erasca, Inc. (ERAS) stock price is $12.64. The stock is traded on NASDAQ under the ticker symbol ERAS. The 52-week range is $1.21 – $24.28.